Cell Source (CLCS) Stock Price

Cell Source Price

NYSE·CLOSED
0.55
​
Market closed

Cell Source stock price

Access this data via the Eulerpool API

Cell Source business model & stock analysis

Cell Source, Inc. operates as a cell therapy company focused on immunotherapy. The company is headquartered in New York City, New York. The company went IPO on 2014-01-14. The firm is primarily focused on the development of immune system management technology (Veto Cell technology). Its lead prospective product is its Veto Cell immune system management technology. Its Veto Cell technology is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is in pre-clinical phase, and its data shows that it provides results in allogeneic (donor-derived) hematopoietic stem cell transplantation (HSCT) by allowing for haploidentical stem cell transplants under a mild conditioning regimen. Its product pipeline includes chimeric antigen receptor (CAR) T-cell therapies, which include VETO CAR-T (with or without HSCT) for B-cell malignancies, Veto Cell kidney transplants, VETO CAR-T for solid tumors, Veto Cell liver transplants, and Veto HSCT for non-malignant disorders. The firm's wholly owned subsidiary is Cell Source Limited (CSL).

Frequently asked questions about Cell Source

Converted at the current exchange rate, the Cell Source share trades at 0.49 EUR (0.55 USD).

The revenue cannot currently be calculated for Cell Source.

The profit cannot currently be calculated for Cell Source.

The P/E ratio cannot be calculated for Cell Source at the moment.

The P/S cannot be calculated for Cell Source currently.

The Eulerpool Quality Score for Cell Source is 2/10.

The ISIN of Cell Source is US15114L1044. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Cell Source is CLCS. The ticker symbol is used to trade Cell Source shares on the stock exchange.

Fair ValueTerminal
0.46 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Jan 14, 2014
ISIN
US15114L1044
Cusip
15114L104
Market capitalization
21.83 M USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
—
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
48.92 %
Last updated Oct 10, 2026, 2:34 PM

Cell Source Peer Group

Cell Source FIGI

CLCS:US · BBG0046WCSY2CLCS:PQ · BBG0046WCTC4CLCS:UV · BBG0046WCTF1

All fundamentals and in-depth analysis of Cell Source

Our stock analysis for Cell Source stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cell Source. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.